BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 26, 2017
View Archived Issues
Flx Bio names first immuno-oncology clinical candidate
Read More
DS-1205b shows promising in vitro and in vivo antitumoral activity
Read More
AVROBIO announces new program in Pompe disease
Read More
Transgene announces launch of Invir.IO platform
Read More
ODM-208 shows promise for the treatment of castration-resistant prostate cancer
Read More
CPL-410-005, a potent E1 inhibitor, shows promise for the treatment of solid tumors
Read More
Arbutus Biopharma provides updated data from phase II study of ARB-1467
Read More
First patient recruited in phase III study of Athenex's KX-01 for actinic keratosis
Read More
Preliminary topline data from phase III trial of Sinovac's varicella vaccine reported
Read More
Bill & Melinda Gates Foundation and Anacor patent boron-containing small molecules
Read More
Shenzhen Targetrx Biotechnology divulges novel ALK inhibitors
Read More
ATM kinase inhibitors presented by AstraZeneca
Read More
Shanghai Institute of Organic Chemistry discloses IDO-1 inhibitors
Read More
The Brigham and Women's Hospital identifies SMOC2 inhibitors
Read More
Allergan reveals new results from CENTAUR study of cenicriviroc in NASH
Read More
Opdivo approved for gastric cancer in Japan
Read More
Hyaluronan predictive of improvement in survival outcomes in PEGPH-20 trial
Read More
Glenmark to return certain crofelemer rights to Napo in 141 countries
Read More
A novel ITPR1 gene mutation found for refractory epilepsy
Read More
ARGX-113 begins phase II study for pemphigus vulgaris, designated orphan drug for myasthenia gravis
Read More
EC approves Symtuza for HIV-1 in adolescents and adults, NDA filed in U.S.
Read More
Akari Therapeutics to advance coversin into phase III studies in PNH
Read More
Asahi Kasei obtains license to Preob from Bone Therapeutics
Read More
U.S. and E.U. orphan drug designation granted to Vivet's gene therapy VTX-801 for Wilson's disease
Read More
EpiVax launches precision immunotherapy venture
Read More
Selexis and OSE sign commercial license agreements to support OSE-172 and OSE-703 programs
Read More
AbbVie, BMS enter agreement to test ABBV-399 with Opdivo in NSCLC
Read More
ProQR reports promising topline data from phase Ib study of QR-010 in cystic fibrosis
Read More
ImmuPharma offers update on Lupuzor program
Read More
Dova Pharmaceuticals submits NDA in U.S. for avatrombopag
Read More
European Commission approves Vimpat for pediatric use
Read More
Keytruda and companion diagnostic approved in U.S. for advanced gastric cancer
Read More
Mallinckrodt completes acquisition of InfaCare Pharmaceutical
Read More
Janssen Biotech receives complete response letter for sirukumab BLA
Read More